X4 Pharmaceuticals, Inc. Expected to Post FY2024 Earnings of ($0.62) Per Share (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Management dropped their FY2024 earnings per share estimates for X4 Pharmaceuticals in a report issued on Thursday, August 8th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.62) for the year, down from their prior estimate of ($0.21). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.55) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.09) EPS.

XFOR has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $5.00 price objective on shares of X4 Pharmaceuticals in a research report on Friday, May 31st. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of X4 Pharmaceuticals in a research report on Friday, June 28th.

X4 Pharmaceuticals Trading Down 4.9 %

Shares of X4 Pharmaceuticals stock opened at $0.61 on Monday. The company has a debt-to-equity ratio of 52.92, a current ratio of 3.71 and a quick ratio of 3.71. The business has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $0.97. X4 Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $1.60. The company has a market capitalization of $101.60 million, a price-to-earnings ratio of -0.86 and a beta of 0.35.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The firm had revenue of $0.56 million during the quarter, compared to the consensus estimate of $52.98 million. During the same period in the prior year, the company earned ($0.33) EPS.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its holdings in X4 Pharmaceuticals by 38.8% in the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after purchasing an additional 13,328 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after acquiring an additional 12,514 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $65,000. Rhumbline Advisers grew its position in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after buying an additional 133,398 shares during the period. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.